Hengrui Medicine (600276.SH): Some drugs have obtained Drug Clinical Trial Approval Notification Letter.

Intelligence Financial APP News, Hengrui Medicine (600276.SH) announced that recently, its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (referred to as the "NMPA"), approving the clinical trials of Atezolizumab Injection, SHR-8068 Injection, Bevacizumab Injection, Injection SHR-1826, Injection SHR-A1904, Injection SHR-A2009, and Injection SHR-A2102, which will be conducted in the near future.